1 Abstract
The reduction in SARS-CoV-2 transmission from contact tracing applications (apps) depends both on the number of contacts notified and on the probability that those contacts quarantine after notification. Referring to the number of days preceding a positive test that contacts are notified as an app’s notification window, we use an epidemiological model of SARS-CoV-2 transmission that captures the profile of infection to consider the trade-off between notification window length and active app-usage. We focus on 5-day and 2-day windows, the lengths used by the NHS COVID-19 app in England and Wales before and after 2nd August 2021, respectively. Short windows can be more effective at reducing transmission if they are associated with higher levels of active app usage and adherence to isolation upon notification, demonstrating the importance of understanding adherence to control measures when setting notification windows for COVID-19 apps.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
TL, MJK and MJT were supported by UKRI through the JUNIPER modelling consortium [grant numberMR/V038613/1]. MJK, RNT and MJT were supported by the Engineering and Physical Sciences ResearchCouncil through the MathSys CDT [grant number EP/S022244/1]. EMH, MJK and MJT were supportedby the Biotechnology and Biological Sciences Research Council [grant number: BB/S01750X/1]. RNTwas supported by UKRI through the Rapid Assistance in Modelling the Pandemic continuity grant [grantnumber: EP/V053507/1]. MJK was supported by the National Institute for Health Research (NIHR) [PolicyResearch Programme, Mathematical & Economic Modelling for Vaccination and Immunisation Evaluation,and Emergency Response; NIHR200411]. MJK is affiliated to the National Institute for Health ResearchHealth Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpoolin partnership with UK Health Security Agency (UKHSA), in collaboration with University of Warwick.MJK is also affiliated to the National Institute for Health Research Health Protection Research Unit (NIHRHPRU) in Genomics and Enabling Data at University of Warwick in partnership with UK Health SecurityAgency (UKHSA). The views expressed are those of the author(s) and not necessarily those of the NHS, theNIHR, the Department of Health and Social Care or UK Health Security Agency. The funders had no rolein study design, data collection and analysis, decision to publish, or preparation of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data availability
Data used to parameterise the study is publicly available and stated within the main manuscript and Supporting Information. Code for the study is available at: https://github.com/tsleng93/AppModelling
